Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Metabolic Brain Disease
Published in: Metabolic Brain Disease 3/2010

01-09-2010 | Original Paper

Brain proton magnetic spectroscopy in long-term treatment of Wilson’s disease patients

Authors: Beata Tarnacka, Wojciech Szeszkowski, Marek Gołębiowski, Anna Członkowska

Published in: Metabolic Brain Disease | Issue 3/2010

Login to get access

Abstract

We reported the brain proton magnetic resonance spectroscopy (MRS) findings in 27 Wilson’s disease (WD) patients treated more than 6 years in neurological (nWD) and hepatic (hWD) subgroups. We investigated four hWD patients, with no improvement and eight with marked improvement; and eight nWD patients with marked improvement and seven with no improvement of clinical status. In nWD patients with improvement the MRS showed significantly higher Cho/Cr, Glx/Cr ratios levels. In hWD patients with no improvement the lower Cho/Cr and in nWD significantly lower NAA/Cr and higher Cho/Cr and Lip/Cr ratios were detected. In nWD patients with improvement the spectroscopic pattern, can be related to gliosis. In patients with no neurological improvement a persistent neuronal dysfunction can occur, perhaps as a result of copper or iron deposition.
Literature
Bonavita S, Di Salle F, Tedeschi G (1999) Proton MRS in neurological disorders. Eur J Radiol 30:125–131CrossRefPubMed
Bottomley P (1986) Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 508:333–348CrossRef
Członkowska A, Galewicz A, Rodo M, Wehr H (1973) Observation on copper metabolism in Wilson’s disease. Acta Univ Carol Med 56:175–178
Haussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, Gerok W, Henning J (1994) Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterol 107:1475–1480
Hoogenraad T (1997) Wilson’s disease. WB. Saunders Company Ttd, London
Horoupian D, Sternlieb I, Scheinberg I (1988) Neuropathological findings in penicillamine—treated patients with Wilson’s disease. Clin Neuropathol 7:62–67PubMed
Kreis R, Ross B, Farrow N, Ackerman R (1992) Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 182:19–27PubMed
Lizardi-Cervera J, Almeda P, Guevara L, Uribe M (2003) Hepatic encephalopathy: a review. Ann Hepatol 2:122–130PubMed
Lucato LT, Barbosa M, Machado A, McKinney A, Bacheschi L, Scaff M, Cerri G, Leite C (2005) Proton MR spectroscopy in Wilson disease: analysis of 36 cases. Am J Neuroradiol 26:1066–1071PubMed
Medici V, Di Leo V, Lamboglia F, Bowlus C, Tseng S, D’Inca R, Irato P, Burra P, Martines D, Strunillo G (2007) Effect of penicillamine and zinc on iron metabolizm in Wilson’s disease. Scand J Gastroenterol 42:1495–1500CrossRefPubMed
Page R, Davie F, MacManus D, Miszkiel K, Walshe J, Miller D (2004) Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson’s disease. Neurology 63:638–643PubMed
Roh J, Lee T, Wie B (1994) Initial and follow up brain MRI findings and correlations with the clinical course in Wilson’s disease. Neurology 44:1064–1068PubMed
Sinha S, Taly B, Ravishankar S, Prashanth L, Venugopal K, Arunodaya G (2006) Wilson’s disease: cranial MRI observations and clinical correlations. Neuroradiology 48:613–621CrossRefPubMed
Spahr L, Burkhard P, Grotzsch H, Hadengue A (2002) Clinical significance of basal ganglia alternations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 17:399–413CrossRefPubMed
Tarnacka B, Szeszkowski W, Gołębiowski M, Członkowska A (2008) MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord 23:1560–1567CrossRefPubMed
Taylor-Robinson SD, Sargentoni J, Marcus CD, Morgan MY, Bryant DJ (1994) Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metab Brain Dis 9:347–359CrossRefPubMed
Verma A, Saraswat V, Krishna R, Nath K, Thomas A, Gupta R (2008) In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure. Liver Int 1478:1095–1103CrossRef
Metadata
Title
Brain proton magnetic spectroscopy in long-term treatment of Wilson’s disease patients
Authors
Beata Tarnacka
Wojciech Szeszkowski
Marek Gołębiowski
Anna Członkowska
Publication date
01-09-2010
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 3/2010
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-010-9214-x

Other articles of this Issue 3/2010

Metabolic Brain Disease 3/2010 Go to the issue

Original Paper

Protein and lipid oxidative damage in streptozotocin-induced diabetic rats submitted to forced swimming test: the insulin and clonazepam effect

Original Paper

Saccadic latency in hepatic encephalopathy: a pilot study

Original Paper

A nonhuman primate model of Alzheimer’s disease generated by intracranial injection of amyloid-beta42 and thiorphan

Review Article

Gene therapy for epilepsy

Original Paper

Brain expression of the water channels Aquaporin-1 and -4 in mice with acute liver injury, hyperammonemia and brain edema

Original Paper

Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice